CluenexVeeva Systems VEEV
Veeva Systems scores excellent on business quality (8.5 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Veeva Systems does
Veeva Systems provides cloud-based software tailored specifically for the global life sciences industry. Pharmaceutical companies and medical device makers pay subscription fees to manage clinical trials, regulatory submissions, and commercial data. Expanding deeper into medtech and clinical data solutions, the company is scaling its platform to capture more core workflows across pharma R&D.
- What it does best
Veeva dominates life sciences CRM and clinical data management, anchoring customers with deep multi-year workflows. Its gross margin sits at 75%, outperforming peer Certara at 62%, reflecting unmatched pricing power inside regulated pharma software.
- The main risk
Trading at $273 against an intrinsic value of $187, the stock prices in aggressive future execution. If enterprise software spending decelerates or AI disruption fears resurface, the wide valuation gap exposes shareholders to sharp multiple contraction.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins sit near 30% alongside a 98th percentile free cash flow margin, proving the business scales efficiently as new software seats are added.
High switching costs and deep regulatory integration lock in enterprise biotech and pharma developers. Its operating margin ranks in the top quartile of its sector at 82nd percentile.
Revenue grew 16.3% to $3.5 billion, accelerating past historical rates as demand for cloud-based clinical and commercial software broadens across life sciences.
Veeva holds $6.5 billion in cash with zero debt, completely eliminating solvency risk. Free cash flow reached $1.6B, scaling rapidly upward and building a fortress balance sheet.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
2 sold $1.5M outside pre-planned sales.
Our sealed record on VEEV
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Veeva Systems scores excellent on the Cluenex quality check (8.5 of 10), measured against its own industry. Profitability is strong, moat strong, growth fast and financial health strong.
In the last 90 days of SEC Form 4 filings: 2 sold $1.5M outside pre-planned sales.
Nov 18, 2026, after the close.
See VEEV today
- Today's verdict on VEEV, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Veeva Systems (VEEV)”, https://cluenex.com/stocks/veev/, data as of Oct 10, 2026.